State of Alaska Department of Revenue Increases Stock Position in Moderna, Inc. (NASDAQ:MRNA)

State of Alaska Department of Revenue increased its position in Moderna, Inc. (NASDAQ:MRNA) by 7.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,568 shares of the company’s stock after purchasing an additional 3,090 shares during the quarter. State of Alaska Department of Revenue’s holdings in Moderna were worth $2,978,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Arkadios Wealth Advisors raised its holdings in Moderna by 2.2% in the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock valued at $764,000 after acquiring an additional 243 shares in the last quarter. Forsta AP Fonden raised its holdings in Moderna by 13.9% in the third quarter. Forsta AP Fonden now owns 68,900 shares of the company’s stock valued at $4,605,000 after acquiring an additional 8,400 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Moderna by 22.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,234 shares of the company’s stock valued at $6,656,000 after acquiring an additional 18,750 shares in the last quarter. E. Ohman J or Asset Management AB acquired a new stake in Moderna in the third quarter valued at $942,000. Finally, Assenagon Asset Management S.A. raised its holdings in Moderna by 79.0% in the third quarter. Assenagon Asset Management S.A. now owns 13,159 shares of the company’s stock valued at $879,000 after acquiring an additional 5,807 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 715 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 3,184 shares of company stock worth $238,531 in the last 90 days. Corporate insiders own 15.70% of the company’s stock.

Moderna Stock Performance

Shares of MRNA opened at $54.36 on Friday. The firm has a 50-day moving average price of $65.70 and a 200 day moving average price of $101.69. The firm has a market capitalization of $20.83 billion, a PE ratio of -3.47 and a beta of 1.66. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 52-week low of $52.26 and a 52-week high of $170.47.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. Moderna’s revenue was down 29.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($3.62) EPS. On average, sell-side analysts anticipate that Moderna, Inc. will post -9.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. JPMorgan Chase & Co. cut shares of Moderna from a “neutral” rating to an “underweight” rating and dropped their target price for the stock from $88.00 to $70.00 in a report on Friday, September 13th. Jefferies Financial Group dropped their target price on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, September 13th. Finally, The Goldman Sachs Group dropped their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a report on Monday, September 16th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $94.65.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.